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154Aortic remodeling after endovascular treatment of
complicated type B aortic dissection with the use of
a composite device design
Joseph V. Lombardi, MD,a Richard P. Cambria, MD,b Christoph A. Nienaber, MD,c
Roberto Chiesa, MD,d Peter Mossop, MD,e Stéphan Haulon, MD,f Qing Zhou, PhD,g and Feiyi Jia, PhD,g
on behalf of the STABLE investigators, Camden, NJ; Boston, Mass; Rostock, Germany; Milan, Italy; Melbourne,
Victoria, Australia; Lille, France; and West Lafayette, Ind
Objective: The purpose of this study is to report updated clinical and aortic remodeling results from the Study for the
Treatment of complicated Type B Aortic Dissection using Endoluminal repair (STABLE) trial, a prospective, multicenter
study evaluating safety and effectiveness of a pathology-speciﬁc endovascular system (proximal stent graft and distal bare
metal stent) for the treatment of complicated type B aortic dissection.
Methods: All 86 enrolled patients (mean age, 59 years; 73.3% men) were treated within 90 days of symptom onset (55 with
acute dissections and 31 with nonacute dissections). Inclusion criteria were branch vessel obstruction/compromise,
impending rupture as evidenced by periaortic effusion/hematoma, resistant hypertension, persistent pain/symptoms, or
aortic growth $5 mm within 3 months (or transaortic diameter $40 mm). Remodeling of the dissected aorta, including
thrombosis of the false lumen and changes in the true lumen, false lumen, and transaortic diameter, were assessed in
patients with available computed tomographic imaging through 2 years.
Results: The 30-day mortality rate was 4.7% (4/86) in the overall patient group (5.5% in acute patients and 3.2% in non-
acute patients). Freedom from all-cause mortality was 88.3% at 1 year and 84.7% at 2 years (no signiﬁcant difference
between acute and nonacute patients). From baseline to 2 years, the true lumen diameter increased signiﬁcantly in the
descending thoracic aorta and the more distal abdominal aorta, along with a decrease in the false lumen diameter in both
aortic segments. A majority of patients had either a stable or shrinking transaortic diameter in the thoracic (80.3% at
1 year and 73.9% at 2 years) or abdominal aorta (79.1% at 1 year and 66.7% at 2 years). Transaortic growth (>5 mm)
occurred predominantly in acute dissections. Consistently, a shorter time from symptom onset to treatment was found to
predict transaortic growth in the abdominal aorta (P [ .03).
Conclusions: Endovascular repair of complicated type B aortic dissection with the use of a composite construct demonstrates
favorable early clinical outcomes and aortic remodeling. However, patients treated in the acute setting may be prone to
aortic growth and may require close observation. Follow-up through 5 years is ongoing. (J Vasc Surg 2014;59:1544-54.)the Department of Surgery, Cooper University Hospital, Camdena;
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4The endovascular treatment of complicated type B
aortic dissection (cTBAD) has evolved with time. Adapta-
tion of the techniques applied for thoracic endovascular
aneurysm repair has been a slow and deliberate process
because of challenges presented by aortic dissections.
With growing interest and demand, an increasing amount
of clinical evidence has accumulated in the past decade,1,2
and endovascular repair of cTBAD has now become a
widely accepted mode of treatment.
The Study for the Treatment of complicated Type B
Aortic Dissection using Endoluminal repair (STABLE)
study assesses the use of a dual-construct device, allowing
for entry tear exclusion with an endograft while providing
intimal support to the remaining aorta with the use of an
uncovered bare metal dissection stent without obstruction
of vital side branches. The 1-year data of the ﬁrst 40 pa-
tients from the STABLE trial were previously published.3
Whereas optimistic results of procedural success and 30-
day mortality rates were reported for this treatment in
the literature,4-7 morphologic changes of the dissected
aorta have not been fully characterized.
This study reports results through 2-year follow-up of
all 86 patients enrolled in the STABLE study, focusing
Table I. Patient demographics and medical history
All Acute Nonacute P valuea
Demographics
Male, % (n/N) 73.3 (63/86) 70.9 (39/55) 77.4 (24/31) .62
Mean age 6 SD (range), years 58.7 6 13.3 (31-86) 58.0 6 13.4 (31-83) 59.8 6 13.3 (31-86) .54
Medical history, % (n/N)
Previous MI 4.7 (4/86) 5.5 (3/55) 3.2 (1/31) >.99
Previous symptomatic CHF 1.2 (1/86) 0 (0/55) 3.2 (1/31) .36
LVEF <20% 0 (0/78) 0 (0/49) 0 (0/29) NA
Previous diagnosis of coronary artery disease 8.4 (7/83) 3.8 (2/52) 16.1 (5/31) .10
Previous diagnosis of cardiac arrhythmia 5.9 (5/85) 3.7 (2/54) 9.7 (3/31) .35
Thromboembolic event 3.5 (3/86) 1.8 (1/55) 6.5 (2/31) .29
Peripheral vascular disease 4.7 (4/85) 3.7 (2/54) 6.5 (2/31) .62
Family history of aneurysm or dissection 7.1 (5/70) 6.7 (3/45) 8.0 (2/25) >.99
Patient history of aneurysm or dissection 9.6 (8/83) 7.7 (4/52) 12.9 (4/31) .46
Hypertension 88.4 (76/86) 81.8 (45/55) 100 (31/31) .012
Previous thoracic surgery or thoracic trauma 2.4 (2/85) 3.7 (2/54) 0 (0/31) .53
Chronic obstructive pulmonary disease 4.8 (4/84) 3.8 (2/53) 6.5 (2/31) .62
Renal failure requiring dialysis 4.7 (4/86) 3.6 (2/55) 6.5 (2/31) .62
Diabetes 5.8 (5/86) 1.8 (1/55) 12.9 (4/31) .054
Previous diagnosis of cerebrovascular disease 10.5 (9/86) 10.9 (6/55) 9.7 (3/31) >.99
Previous endarterectomy 0 (0/86) 0 (0/55) 0 (0/31) NA
Smoking 57.9 (44/76) 63.3 (31/49) 48.1 (13/27) .23
CHF, Congestive heart failure; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NA, not applicable; SD, standard deviation.
aP values for comparison between patients with acute dissections vs chronic dissections.
JOURNAL OF VASCULAR SURGERY
Volume 59, Number 6 Lombardi et al 1545on aortic remodeling of the dissected aorta after endovas-
cular treatment with the composite device design.
METHODS
STABLE study. STABLE is a prospective, non-
randomized, multicenter clinical study that evaluates the
safety and effectiveness of a pathology-speciﬁc endovascular
system (Zenith Dissection Endovascular System; Cook
Medical, Bloomington, Ind). The study was conducted at
institutions in the United States, Europe, and Australia and
has completed its enrollment of a total of 86 patients
(between December 2007 and February 2012). Study
design, patient eligibility, and 12-month results from the
ﬁrst 40 enrolled patients were previously published.3 In
brief, patients with cTBAD were eligible if they met one or
more of the following criteria: branch vessel obstruction/
compromise, impending rupture as evidenced by periaortic
effusion/hematoma, resistant hypertension, persistent
pain/symptoms, or aortic growth$5 mm within 3 months
(or transaortic diameter $40 mm).
All patients enrolled in this study were treated within
90 days of symptom onset, including 55 patients treated
within the acute phase (within 14 days of symptom onset)
and 31 patients treated beyond the acute phase (or non-
acute phase; >14 days of symptom onset). Because of
the relatively small number of patients treated in the non-
acute phase, results for these patients were not further
divided into subacute and chronic groups.
The study’s primary end point was 30-day mortality.
All patients were to be followed up for 5 years after the
initial endovascular treatment. The study was performed
according to the Declaration of Helsinki II, with study
approval obtained from the relevant ethics committee ateach institution. All patients signed an informed consent
to participate in the study.
Device description. The Zenith Dissection Endovas-
cular System is a modular system speciﬁcally designed to
treat aortic dissections. The system comprises the Zenith
TX2 TAA Endovascular Graft with Pro-Form (proximal
stent graft) and the Zenith Dissection Endovascular Stent
(distal bare metal stent). During the implantation proce-
dure, the TX2 stent graft component was ﬁrst deployed to
cover the primary entry tear. Subsequent deployment of
the bare metal stent component was recommended if
branch vessel obstruction or false lumen perfusion persisted
and was performed at the discretion of each implanting
physician. Detailed descriptions of the device, its implant-
ing techniques, and recommendations for use of the bare
stent were described previously.3
Data analysis. Data were managed by a centralized
data-coordinating center, MED Institute, Inc. Statistical
analyses were performed with the use of SAS for Windows
(release 9.1 or higher; SAS Institute Inc, Cary, NC) or
other widely accepted statistical software. Continuous
variables are reported as means and standard deviations
unless otherwise noted, and categorical variables are re-
ported as percentages. P values #.05 were considered
signiﬁcant.
Patients underwent clinical and imaging evaluation
before discharge, at 1, 6, and 12 months, and yearly there-
after up to 5 years. Multiplanar contrast-enhanced
computed tomographic angiography (CTA) was per-
formed unless contraindicated before the procedure and
during follow-up. The study protocol recommends the
use of region of interest in the aortic arch to monitor
enhancement before scan, and, for phase-delayed CT, a
Table II. Dissection characteristics
All,
% (n/N)
Acute,
% (n/N)
Nonacute,
% (n/N) P valuea
Indications for treatment
Branch vessel obstruction or compromise 65.1 (56/86) 69.1 (38/55) 58.1 (18/31) .35
Periaortic effusion/hematoma 16.3 (14/86) 20.0 (11/55) 9.7 (3/31) .36
Resistant hypertension 54.7 (47/86) 54.5 (30/55) 54.8 (17/31) >.99
Persistent pain/symptoms 75.6 (65/86) 81.8 (45/55) 64.5 (20/31) .12
Transaortic growth $5 mm within 3 mo (or transaortic diameter $40 mm) 48.8 (42/86) 34.5 (19/55) 74.2 (23/31) <.001
Anatomical featuresb
Primary tear
In LSA 1.2 (1/82) 0 (0/52) 3.3 (1/30) .65
Aorta at LSA 19.5 (16/82) 21.2 (11/52) 16.7 (5/30)
Descending thoracic aorta 78.0 (64/82) 76.9 (40/52) 80.0 (24/30)
Aorta at SMA 1.2 (1/82) 1.9 (1/52) 0 (0/30)
Proximal aspect of dissection
Proximal to LSA 10.6 (9/85) 12.7 (7/55) 6.7 (2/30) .16
In LSA 5.9 (5/85) 9.1 (5/55) 0 (0/30)
Aorta at LSA 72.9 (62/85) 70.9 (39/55) 76.7 (23/30)
Descending thoracic aorta 10.6 (9/85) 7.3 (4/55) 16.7 (5/30)
Distal aspect of dissection
Descending thoracic aorta 1.4 (1/69) 2.4 (1/42) 0.0 (0/27) .44
Aorta at celiac 1.4 (1/69) 0 (0/42) 3.7 (1/27)
Aorta at SMA 1.4 (1/69) 0 (0/42) 3.7 (1/27)
In renal arteries 2.9 (2/69) 4.8 (2/42) 0 (0/27)
Aorta at renal arteries 1.4 (1/69) 2.4 (1/42) 0 (0/27)
Infrarenal abdominal aorta 14.5 (10/69) 11.9 (5/42) 18.5 (5/27)
In or below common iliac arteries 76.8 (53/69) 78.6 (33/42) 74.1 (20/27)
LSA, Left subclavian artery; SMA, superior mesenteric artery.
aP values for comparison between patients with acute dissections vs chronic dissections.
bThe denominator for each anatomical measurement reﬂects the number of patients with adequate CT imaging analyzed by the core laboratory.
Fig 1. Summary of device combinations. TX2 refers to the
proximal TX2 stent graft; stent refers to the bare metal dissection
stent.
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CT imaging was evaluated by each investigative site and
centrally reviewed by an independent core laboratory
blinded to the site assessments. Core lab review was per-
formed with standardized protocols, deﬁnitions, and multi-
ple quality assurance processes under the direction of
a board-certiﬁed diagnostic radiologist with extensive expe-
rience. Unless indicated otherwise, data reported herein
reﬂect the results from the core laboratory analysis.
Aortic remodeling was assessed separately for the
descending thoracic aorta and the abdominal aorta (divided
by the celiac artery). Status of the false lumen was qualita-
tively assessed on CTA as patent (evidence of contrast
without evidence of thrombus), partially thrombosed (evi-
dence of both contrast and thrombus), or completely
thrombosed (evidence of thrombus without evidence of con-
trast) in the descending thoracic aorta and abdominal aorta.
The maximum transaortic diameter, as well as the true
lumen and false lumen diameter at the corresponding plane,
was obtained for the descending thoracic aorta and abdominal
aorta. The changes in the true lumen, false lumen, and trans-
aortic diameters over time were analyzed with the use of a
mixed model, which accounts for changes within each patient
and allows for statistical comparisons between time points.
Aortic growth in the descending thoracic aorta or the
abdominal aorta was deﬁned as a >5 mm increase in the
maximum transaortic diameter at a follow-up time point
as compared with the measurement at postprocedureexamination (or 30-day if postprocedure examination was
not available). A generalized linear model was used to assess
baseline characteristics that may be predictive of aortic growth.
RESULTS
This study reports available clinical and anatomical re-
sults through 2 years after the initial endovascular proce-
dure, comprising data as of March 11, 2013. Of 86
patients enrolled in this study, 13 patients died (as
Table III. Summary of all deaths occurring within 2 years
Patient Days Cause of death
CEC adjudication of relationship
to dissection repair
Acute 5 Stroke Related
Acute 11 Aortic rupture Related
Acute 11 Stroke Related
Nonacute 29 Unknown Unable to determine
Nonacute 33 Retrograde dissection causing aortic root
dilation and cardiac tamponade
Related
Acute 81 Aortic rupture; right coronary artery
occlusion
Related
Nonacute 99 Acute intramural hematoma of the
ascending aorta; right coronary artery
obstruction
Not related (pre-existing condition)
Nonacute 137 Non-Hodgkin lymphoma Not related
Acute 196 Hypotensive shock after aortic rupture Related (to a secondary intervention to
treat a type I entry-ﬂow)
Nonacute 211 Cardiocirculatory arrest after acute
respiratory failure
Related (to a secondary intervention to
treat device migration)
Acute 513 Melanoma Not related
Acute 561 Suspicion of aortic rupture and acute
abdomen
Unable to determine
Nonacute 668 Pneumonia Not related
CEC, Clinical events committee.
Fig 2. Kaplan-Meier analysis of freedom from all-cause mortality.
Vertical bars represent 95% conﬁdence intervals; dots represent
censored data.
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study within 2 years. CT imaging was available in all 86 pa-
tients at preprocedure examination, in 79 patients at post-
procedure examination, 67 patients at 12 months, and 48
patients at 24 months.
Dissection characteristics and devices used. Of the
total 86 patients (73.3% men; mean age, 59 years) enrolled
in the STABLE study, 55 patients were treated in the acute
phase of dissection (symptom onset to treatment: 4.2 6
3.7 days; range, 0-14 days) and 31 patients were treated
in the nonacute phase (symptom onset to treatment:
40.5 6 22.5 days; range, 15-86 days). Patient de-
mographics and medical history are summarized in Table I.Age, sex, and baseline comorbidities were similar between
patients treated in acute and nonacute phases; hypertension
was signiﬁcantly more prevalent in patients treated in the
nonacute phase.
As shown in Table II, the median number of clinical
indications was three per patient (range, 1-5) in the overall
patient group. The majority of patients (73.3%, 63/86)
presented with impending aortic rupture (indicated by
periaortic effusion or hematoma) and/or branch vessel
malperfusion (based on clinical and/or imaging evaluation
by the investigative sites). Signiﬁcantly more nonacute dis-
sections met the criterion of rapid transaortic growth
($5 mm within 3 months) or a large baseline transaortic
diameter ($40 mm) (74.2% vs 34.5%; P < .001); most
of these patients also met at least one clinical criterion.
No signiﬁcant difference was seen for other indications
between acute and nonacute dissections. Anatomically, dis-
sections treated in this study were extensive: of patients
available for assessing the distal aspect of dissection,
98.6% (68/69) were classiﬁed as DeBakey 3b (with dissec-
tion extending below the diaphragm). Anatomical features
including the locations of the primary tear and proximal or
distal aspect of dissections were similar between patients
treated in the acute and nonacute phases.
All patients received implantation of one or more TX2
stent grafts, and 80 patients (93.0%) received placement of
at least one dissection stent. The combination of one TX2
component and one or more dissection stents was used
most frequently in this study (Fig 1).
Clinical outcomes: mortality, morbidity, and sec-
ondary interventions. The 30-day mortality rate was 4.7%
(4/86) for the overall patient group, 5.5% (3/55) for pa-
tients with acute dissections, and 3.2% (1/31) for patients
with nonacute dissections (P > .99). As summarized in
Table IV. Summary of selected clinical outcomes
All,
% (n/N)
Acute,
% (n/N)
Nonacute,
% (n/N)
P
valuea
Rupture
<30 days 1.2 (1/86) 1.8 (1/55) 0 (0/31) >.99
31-365 days 2.4 (2/82) 3.8 (2/52) 0 (0/30) .53
366-730 days 2.7 (2/75) 2.0 (1/49) 3.8 (1/26) >0.99
Renal failure
<30 days 8.1 (7/86) 10.9 (6/55) 3.2 (1/31) .41
31-365 days 1.2 (1/82) 1.9 (1/52) 0 (0/30) >.99
366-730 days 1.3 (1/75) 0 (0/49) 3.8 (1/26) .35
Bowel ischemia
<30 days 1.2 (1b/86) 1.8 (1/55) 0 (0/31) >.99
31-365 days 1.2 (1b/82) 1.9 (1/52) 0 (0/30) >.99
366-730 days 0 (0/75) 0 (0/49) 0 (0/26) NA
Stroke
<30 days 7.0 (6/86) 10.9 (6/55) 0 (0/31) .08
31-365 days 1.2 (1/82) 1.9 (1/52) 0 (0/30) >.99
366-730 days 0 (0/75) 0 (0/49) 0 (0/26) NA
Paraplegia
<30 days 1.2 (1/86) 1.8 (1/55) 0 (0/31) >.99
31-365 days 0 (0/82) 0 (0/52) 0 (0/30) NA
366-730 days 0 (0/75) 0 (0/49) 0 (0/26) NA
Paraparesis/spinal
cord shock
<30 days 1.2 (1/86) 0 (0/55) 3.2 (1/31) .36
31-365 days 0 (0/82) 0 (0/52) 0 (0/30) NA
366-730 days 1.3 (1/75) 2.0 (1/49) 0 (0/26) > .99
TIA
<30 days 1.2 (1/86) 1.8 (1/55) 0 (0/31) >.99
31-365 days 0 (1/82) 0 (0/52) 0 (0/30) NA
366-730 days 0 (0/75) 0 (0/49) 0 (0/26) NA
Retrograde
dissection
<30 days 4.7 (4/86) 3.6 (2/55) 6.5 (2/31) .62
31-365 days 3.7 (3/82) 5.8 (3/52) 0 (0/30) .30
366-730 days 0 (0/75) 0 (0/49) 0 (0/26) NA
NA, Not applicable; TIA, transient ischemic attack.
aP values for comparison between patients with acute dissections vs chronic
dissections.
bSame patient.
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in 2 patients, aortic rupture in the setting of chronic
hypertension in 1 patient, and unknown in 1 patient. An
additional nine deaths (four acute, ﬁve nonacute) occurred
between 31 days and 24 months, four of which (one acute,
three nonacute) were adjudicated as unrelated to the
dissection repair by the clinical events committee.
For the overall patient group, freedom from all-cause
mortality was 88.3% at 1 year and 84.7% at 2 years
(Fig 2), and freedom from dissection-related mortality
(as adjudicated by the clinical events committee) was
90.6% at 1 year and 89.3% at 2 years. Between the acute
and nonacute patients groups, there was no signiﬁcant
difference in freedom from all-cause mortality (87.1% vs
76.7% at 2 years; log-rank test, P ¼ .09) or from
dissection-related mortality (88.9% vs 90.1% at 2 years;
log-rank test, P ¼ .89).
The rates of notable clinical events are summarized in
Table IV. No signiﬁcant differences were observed for
the event rates between the acute and nonacute patient
groups. Five patients had aortic rupture within 2 years,
with one occurring within 30 days, two between 31 days
and 1 year, and two between 1 and 2 years. The occurrence
of other adverse events, including stoke, paraplegia, renal
failure, bowel ischemia, and retrograde dissection, was
mostly limited to the ﬁrst 12-month period.
There were no conversions to open surgical repair.
Among the overall patient group, 21 patients underwent
a total of 26 secondary interventions within 2 years, with
the cumulative freedom from secondary interventions of
73.3%. The most common cause for the secondary inter-
ventions (a patient can be treated for multiple causes)
was persistent entry-ﬂow and/or sealing of re-entry tears
(n ¼ 11), followed by malperfusion/ischemia (n ¼ 5),
type A or retrograde dissection (n ¼ 5), device migration,
separation, or kink (n ¼ 4), aneurysm growth or degener-
ation (n ¼ 3), and aortic rupture (n ¼ 2). Of note, there
were no secondary interventions performed for malperfu-
sion/ischemia beyond 30 days. Freedom from secondary
interventions was similar between patients with acute dis-
sections (72.7% at 2 years) and those with nonacute dissec-
tions (74.7% at 2 years; log-rank test, P ¼ .93).
Aortic remodeling: False lumen thrombosis. As
shown in Table V, a completely thrombosed false lumen
in the thoracic aorta (down to the celiac artery) increased
signiﬁcantly from 0% at preprocedure examination to
32.8% at 12 months and 43.5% at 24 months in the overall
patient group (Cochrane Armitage Trend test, P < .001).
All thoracic false lumens were either partially or completely
thrombosed after the 30-day follow-up. In comparison, the
rates of complete thrombosis in the abdominal false lumen
were lower.
A patent false lumen was seen more frequently in acute
dissections before treatment; however, there was no signif-
icant difference in the false lumen status (either the thoracic
or abdominal aorta) between acute and nonacute dissec-
tions during follow-up.Aortic remodeling: True and false lumens. Changes
in the average diameters of the true lumen, false lumen,
and total aortic lumen (ie, transaortic) were estimated
from a mixed model, as shown in Table VI and illus-
trated in Fig 3. Overall, from baseline (preprocedure) to
2 years, a signiﬁcant increase in the average true lumen size,
along with a signiﬁcant decrease in the false lumen size, was
observed in both the thoracic aorta and the abdominal
aorta. Such remodeling was seen in both acute and
nonacute dissections, occurring early after the endovascular
treatment, with subsequent changes occurring mostly
within 12 months.
True lumen. The endovascular treatment led to early,
signiﬁcant expansion of the true lumen in both the
descending thoracic aorta and the abdominal aorta, as
seen at the postprocedure time point. The true lumen
continued to expand signiﬁcantly in the thoracic aorta
during follow-up, whereas its size remained relatively stable
in the abdominal aorta. Trends in true lumen expansion
were similar between acute and nonacute dissections.
Table V. False lumen status in the thoracic aorta and abdominal aorta
All,
% (n/N)
Acute,
% (n/N)
Nonacute,
% (n/N) P valuea
Thoracic aorta
Preprocedure .036
Patent 39.3 (33/84) 48.1 (26/54) 23.3 (7/30)
Partially thrombosed 60.7 (51/84) 51.9 (28/54) 76.7 (23/30)
Completely thrombosed 0 (0/84) 0 (0/54) 0 (0/30)
Postprocedure .67
Patent 1.3 (1/76) 2.1 (1/47) 0 (0/29)
Partially thrombosed 88.2 (67/76) 85.1 (40/47) 93.1 (27/29)
Completely thrombosed 10.5 (8/76) 12.8 (6/47) 6.9 (2/29)
12 months .41
Patent 0 (0/64) 0 (0/40) 0 (0/24)
Partially thrombosed 67.2 (43/64) 62.5 (25/40) 75.0 (18/24)
Completely thrombosed 32.8 (21/64) 37.5 (15/40) 25.0 (6/24)
24 months
Patent 0 (0/46) 0 (0/31) 0 (0/15) .36
Partially thrombosed 56.5 (26/46) 51.6 (16/31) 66.7 (10/15)
Completely thrombosed 43.5 (20/46) 48.4 (15/31) 33.3 (5/15)
Abdominal aorta
Preprocedure .001
Patent 58.1 (50/86) 70.9 (39/55) 35.5 (11/31)
Partially thrombosed 38.4 (33/86) 27.3 (15/55) 58.1 (18/31)
Completely thrombosed 1.2 (1/86) 1.8 (1/55) 0 (0/31)
Not applicable 2.3 (2/86) 0 (0/55) 6.5 (2/31)
Postprocedure .85
Patent 38.5 (30/78) 41.7 (20/48) 33.3 (10/30)
Partially thrombosed 53.8 (42/78) 52.1 (25/48) 56.7 (17/30)
Completely thrombosed 5.1 (4/78) 4.2 (2/48) 6.7 (2/30)
Not applicable 2.6 (2/78) 2.1 (1/48) 3.3 (1/30)
12 months .12
Patent 7.6 (5/66) 11.9 (5/42) 0 (0/24)
Partially thrombosed 80.3 (53/66) 71.4 (30/42) 95.8 (23/24)
Completely thrombosed 9.1 (6/66) 11.9 (5/42) 4.2 (1/24)
Not applicable 3.0 (2/66) 4.8 (2/42) 0 (0/24)
24 months .39
Patent 10.9 (5/46) 16.1 (5/31) 0 (0/15)
Partially thrombosed 73.9 (34/46) 67.7 (21/31) 86.7 (13/15)
Completely thrombosed 13.0 (6/46) 12.9 (4/31) 13.3 (2/15)
Not applicable 2.2 (1/46) 3.2 (1/31) 0 (0/15)
aP values for comparison between patients with acute dissections vs chronic dissections.
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lumen decreased in size signiﬁcantly in both the thoracic
aorta and abdominal aorta. In the thoracic aorta, the false
lumen continued to decrease in size during follow-up, with
a larger shrinkage observed in nonacute dissections. In the
abdominal aorta, the false lumen remained stable in non-
acute dissections; however, a small yet signiﬁcant increase
in the false lumen size was seen in acute dissections after
postprocedure examination.
Aortic remodeling: Transaortic diameter. The
average transaortic diameters generally increased slightly af-
ter surgery. During the subsequent follow-up, the trans-
aortic diameter of the thoracic aorta remained relatively
stable in the acute dissections, while showing a signiﬁcant
decrease in nonacute dissections. In the abdominal aorta,
the transaortic diameter increased signiﬁcantly in acute
dissections, mostly attributed to an increased false lumen
size, whereas the transaortic diameter stayed relatively
stable in nonacute dissections.Changes in the maximum transaortic diameter were
further categorized into growth (increase of >5 mm),
shrinkage (decrease of >5 mm), or no change (increase or
decrease within 5 mm), as shown in Table VII. In the overall
patient group, a majority had either a stable or a shrinking
aorta in the thoracic segment (80.3% at 1 year and 73.9%
at 2 years) or the abdominal segment (79.1% at 1 year
and 66.7% at 2 years). A >5 mm growth in the transaortic
diameter was observed more frequently in acute dissections
than in nonacute dissections, with a signiﬁcant difference
seen at 12 months for the thoracic aorta (P ¼ .012) and
at 24 months for the abdominal aorta (P ¼ .008).
A generalized linear model was used to assess baseline
factors that may be predictive of transaortic growth. An
outcome of growth in this model was deﬁned as a >5 mm
increase in the maximum transaortic diameter within
24 months as compared with postprocedure examination
(or 30-day if postprocedure examination was not available).
The factors examined include age, Society for Vascular
Table VI. Changes the true lumen, false lumen, and transaortic diameters as estimated by a mixed model
Variables Postprocedure 12 months 24 months
LSM (SE)a, mm Preprocedure
Changeb from
preprocedure P valuec
Changeb from
postprocedure P valuec
Changeb from
12 months P valuec
TL e Thoracic
Acute 20.9 (1.1) þ9.8 (1.5) <.001 þ3.7 (1.7) .03 þ0.9 (1.8) .60
Nonacute 19.5 (1.2) þ8.6 (1.5) <.001 þ4.8 (1.7) .006 þ0.5 (1.8) .80
TL e Abdominal
Acute 14.3 (1.2) þ11.6 (1.0) <.001 0.4 (1.4) .77 þ1.1 (1.2) .33
Nonacute 15.3 (1.5) þ7.3 (1.4) <.001 þ1.4 (1.9) .47 þ0.6 (1.7) .74
FL eThoracic
Acute 18.7 (1.2) 7.1 (1.5) <.001 2.1 (1.8) .26 þ0.3 (1.8) .86
Nonacute 26.9 (1.5) 7.2 (1.5) <.001 8.1 (2.0) <.001 þ0.3 (1.8) .88
FL e Abdominal
Acute 18.2 (1.0) 9.6 (1.0) <.001 þ3.7 (1.4) .009 þ0.4 (1.2) .74
Nonacute 20.9 (1.4) 6.3 (1.3) <.001 0.3 (1.8) .87 0.5 (1.6) .75
Transaortic e Thoracic
Acute 39.5 (0.9) þ2.7 (0.6) <.001 þ1.5 (0.9) .12 þ0.9 (0.7) .20
Nonacute 46.2 (1.3) þ1.5 (0.7) .06 3.4 (1.1) .004 þ0.4 (0.9) .69
Transaortic e Abdominal
Acute 32.4 (0.9) þ1.9 (0.6) .002 þ3.6 (0.9) <.001 þ1.6 (0.7) .03
Nonacute 36.1 (1.4) þ1.0 (0.7) .12 þ1.0 (1.0) .35 þ0.1 (0.8) .88
FL, False lumen; LSM, least-square means estimated from the general linear model; SE, standard error; TL, true lumen.
aBoth LSM and SE were calculated from the mixed model.
bPlus sign indicates an increase; minus sign indicates a decrease in the measurement from the previous time point.
cP value corresponds to the change in diameter between the two time points as shown on its left.
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(SVS-ISCVS) risk score of hypertension, indications for treat-
ment (categorized into “impending rupture or malperfusion”
and “other criteria”), duration from symptom onset to treat-
ment, baseline transaortic diameter, and baseline presence of
secondary tears. Consistent with the above observation of
more frequent growth in acute dissections, shorter duration
from symptom onset to treatment was the only signiﬁcant
predictor of transaortic growth in the abdominal aorta
(P ¼ .03). No signiﬁcant predictors were identiﬁed for trans-
aortic growth in the thoracic aorta.
DISCUSSION
The indications for treatment of cTBAD in this report
represent the most common circumstances requiring inter-
vention beyond medical management. The threatening
ﬁndings of periaortic hematoma and effusion along with
malperfusion represented 73% of our patient population.
The mean number of 3 indications per patient also suggests
that the study cohort was representative of complicated
circumstances. The need to be aggressive with patients pre-
senting with recurrent and persistent pain and hypertension
is well documented and worth reemphasizing.3,8
Mortality and morbidity. The 30-day mortality of
4.7% compares favorably with the literature on endovas-
cular repair of cTBAD.2,9-11 Beyond the initial 30-day
period comes the important process of follow-up and
close observation. In this study, several patients had
retrograde type A dissection (3/7) and aortic rupture (4/5)
outside of the 30-day window. The etiology of retrograde
dissection cannot be solely ascribed to technique becausethree of seven patients were beyond 30 days with no
CT evidence of ascending aorta involvement on prior
follow-up CT scans. An important contributing factor was
placement of the stent graft in a dissected sealing zone
segment of the aorta (4/7 patients). Still, manipulation of
the dissected thoracic aorta will always have a risk for
retrograde propagation in the postprocedural phase and
beyond.12,13 The importance of long-term follow-up after
endovascular repair of dissected thoracic aorta is also
echoed in other reports.14-16
The incidence of stroke was observed exclusively
among the acute patients, with the majority (6/7) present-
ing within 30 days. These patients uniformly had anterior-
posterior, bi-hemispheric embolic stroke. The distribution
of these infarcts suggests a possible technical component
with catheter and device manipulation, and, more impor-
tantly, reemphasizes the fragility of the aorta in the acute
phase and the need to be meticulous with planning, device
preparation, and endovascular technique.
False lumen thrombosis. The relevance of false
lumen thrombosis with long-term outcome has been
demonstrated in earlier studies.17,18 In the present study, a
signiﬁcant increase in complete thrombosis was seen in the
thoracic false lumen over timedabout half of the patients
achieved complete thrombosis at 2 years. Still, many
patients had incomplete false lumen thrombosis during
follow-up, and persistent ﬂow into the abdominal false
lumen was even more prevalent. Such ﬂow was primarily
through intercostal collateral sources or through re-entry
tears, the treatment of which was not mandatory and was
performed at the discretion of implanting physicians.
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Fig 3. Maximum diameters (least-square means estimated from a mixed model) of the true lumen, false lumen, and
total lumen (or transaortic) in the descending thoracic aorta and the abdominal aorta. Data were plotted separately for
acute dissections and nonacute dissections. Vertical bars represent 95% conﬁdence intervals. The number of computed
tomographic (CT) scans analyzed by the core lab was provided for each measurement under the corresponding time
point. Detailed values of the measurements and comparisons between time points are presented in Table IV.
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lumen thrombosis in the thoracic aorta, as observed in the
current study, may be related to a rather stringent deﬁnition
of false lumen involvement (entire segment from the left
subclavian artery to celiac) and probably is inﬂuenced by
the strategy of minimal proximal coverage followed by distal
bare support. Although minimally discussed, other strate-
gies may favor more extensive thoracic coverage, which is
believed to give a greater rate of false lumen thrombosis.19
Greater coverage of the thoracic aorta may result in greater
false lumen thrombosis but also increases the risk of spinal
ischemia, which was notably low in this study.
Size of dissected aorta. The importance of aortic
remodeling after endovascular repair of dissection has
been well described.17,20 In the present study, despite the
true lumen augmentation and false lumen regression
observed overall after treatment, the fate of the dissected
abdominal aorta remains unclear. The nonacute patients
had a signiﬁcant decrease in thoracic aortic diameter and a
stable abdominal aortic diameter. However, in acutely
treated patients, the dissected abdominal aorta appears to
be more prone to aortic expansion over time.
Our ﬁndings suggest that in acute dissections, growth
in the abdominal aorta after treatment was mainlyattributed to an expansion in the false lumen, whereas
the true lumen remained unchanged in size. As mentioned
earlier, persistent ﬂow into the abdominal false lumen was
present in a majority of patients during follow-up.
Continued pressurization in the false lumen may lead to
its expansion as the aortic wall continues to weaken during
follow-up.
However, persistent false lumen ﬂow does not appear
to be the sole factor leading to aortic growth. We found
that a large portion of patients with persistent false lumen
ﬂow in the thoracic or abdominal aorta did not have
growth in the respective aortic segments. Also, we found
that the status of false lumen after repair was similar be-
tween acute and nonacute dissections, which had very
distinctive outcomes in terms of aortic growth. Therefore,
false lumen ﬂow does not appear to be the main factor
causing the different growth patterns between these
groups. The pathophysiological features of the dissected
aorta at the time of treatment (and how the aorta responds
to changed hemodynamics) may be an important factor.
Aortic growth after endovascular treatment of type B
aortic dissection has been reported by others. A report by
Sobocinski et al21 describes a signiﬁcant increase in abdom-
inal aortic diameter for a cohort of acute (0-14 days)
Table VII. Changes in the maximum transaortic diameter in the descending thoracic aorta and abdominal aorta,
categorized by growth (>5 mm increase), shrinkage (>5 mm decrease), or no change (increase or decrease within 5 mm)
All,
% (n/Na)
Acute,
% (n/Na)
Nonacute,
% (n/Na) P valueb
Thoracic aorta
6 months .52
Growth 19.7 (13/66) 22.7 (10/44) 13.6 (3/22)
No change 63.6 (42/66) 61.4 (27/44) 68.2 (15/22)
Shrinkage 16.7 (11/66) 15.9 (7/44) 18.2 (4/22)
12 months .012
Growth 19.7 (13/66) 29.3 (12/41) 4.0 (1/25)
No change 60.6 (40/66) 53.7 (22/41) 72.0 (18/25)
Shrinkage 19.7 (13/66) 17.1 (7/41) 24.0 (6/25)
24 months .07
Growth 26.1 (12/46) 35.5 (11/31) 6.7 (1/15)
No change 60.9 (28/46) 58.1 (18/31) 66.7 (10/15)
Shrinkage 13.0 (6/46) 6.5 (2/31) 26.7 (4/15)
Abdominal aorta
6 months .15
Growth 16.4 (10/61) 21.4 (9/42) 5.3 (1/19)
No change 73.8 (45/61) 69.0 (29/42) 84.2 (16/19)
Shrinkage 9.8 (6/61) 9.5 (4/42) 10.5 (2/19)
12 months .06
Growth 20.9 (14/67) 28.6 (12/42) 8.0 (2/25)
No change 73.1 (49/67) 66.7 (28/42) 84.0 (21/25)
Shrinkage 6.0 (4/67) 4.8 (2/42) 8.0 (2/25)
24 months .008
Growth 33.3 (15/45) 46.7 (14/30) 6.7 (1/15)
No change 60.0 (27/45) 50.0 (15/30) 80.0 (12/15)
Shrinkage 6.7 (3/45) 3.3 (1/30) 13.3 (2/15)
aThe denominator reﬂects the number of patient in whom the maximum diameter measurements were available at both baseline (postprocedure or 1 month)
and a follow-up time point.
bP values for comparison of growth and nongrowth (ie, no change and shrinkage) categories between patients with acute dissections vs chronic dissections.
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with our ﬁndings. This report observed a transaortic
growth >5 mm in 25% and 33% of the patients at
12 months for thoracic aorta and abdominal aorta, respec-
tively. Another report by Sayer et al22 reviewed both acute
and chronic dissections treated with endovascular repair, in
which their acute cohort showed a 20% expansion rate of
the thoracic aorta with endografting alone. Although this
report did include nine patients with either intra-mural he-
matoma or penetrating ulcer, which were not included in
this study, a thoracic false lumen thrombosis rate of just
over 50% at 24 months does parallel our data at 48.4%.
Expansion of the uncovered aorta distal to the stent graft
was also observed in 16% of acutely treated patients in a
study by Resch et al23 Moreover, in a recent report from
the International Registry of Acute Aortic Dissection regis-
try, aortic growth or new aneurysm occurred in up to 73%
of patients at 5 years after endovascular repair of acute
TBAD, highlighting the risk of disease progression in this
patient population.24 On the basis of these ﬁndings,
long-term aortic dilatation, particularly in the abdominal
aorta, is a phenomenon that must be surveyed methodically
on follow-up imaging.
As we understand the natural history of cTBAD better,
it is unlikely that endovascular therapy actually “treats” or
“resolves” the dissection. The idea of “management” maybemore appropriate because it denotes a long-term commit-
ment to patients in whom the dissected aorta is prone to
complications.Although themajority of patients inour study
presentedwith a grave situation and resultedwith a favorable
clinical outcome, progression of disease in the long term
must be monitored closely. The management process then
ensues with a focus on false lumen status, with secondary
interventions performed as needed, to minimize the risk of
aortic rupture from aneurysmal growth/degeneration.
Bare metal dissection stent. Previous reports indicate
that remodeling (true lumen expansion and false lumen
shrinking) of the dissected aorta is often limited to the
thoracic aorta with stent graft coverage.22,25,26 With the
use of the distal bare metal stent, however, signiﬁcant true
lumen expansion was achieved not only in the thoracic
aorta but also in the distal abdominal aorta in the current
study. This ﬁnding is also consistent with the single-center
volumetric analysis on the same system.20 Besides true
lumen expansion, placement of the bare metal stent may
help stabilize the intimal ﬂap while allowing for interro-
gation of the target vessels through the interstices of the
stent to reestablish ﬂow.
The limitations of this study include 24-monthmorpho-
metric analysis in a subset of patients with adequate imaging
for core lab analysis as well as the lack of longer-term follow-
up. The limited sample size in the acute and nonacute groups
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two groups. Given the single-arm design of the STABLE
study, the current analysis was performed mainly to charac-
terize aortic remodeling after treatment with the composite
system rather to than delineate the role of the bare stents. In
addition, because the study did not collect information on
the length of aorta encompassed by covered stent grafts
and bare stents, we were not able to examine how the extent
of coverage affects aortic remodeling.
CONCLUSIONS
The use of proximal endografting combined with a distal
bare metal stent produces favorable mortality rates and among
the lowest reported paraplegia rates. However, our data sug-
gest that patients treated in the acute setting are more prone
to abdominal aortic dilatation. This potential risk should be
recognized when patients must undergo immediate dissection
repair for life-threatening symptoms such as acutemalperfusion
or impending/frank aortic rupture. Data accumulation is
currently ongoing to obtain follow-up results through 5 years.
Longer-term follow-up results, particularly the need for sec-
ondary interventions, are required to understand the effective-
ness of endovascular repair for the treatment of cTBAD.
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are right now with this technology, what length uncovered stent
do you currently favor when you’re approaching a patient?
Dr Joseph V. Lombardi (Camden, NJ). Based on the data
that we’re seeing now, we’re observing a lot of increased false
lumen ﬂow. I think the natural tendency of everyone is to increase
your coverage zone down to the celiac artery for your proximal
piece. However, the STABLE trial has demonstrated a very low
1.2% paraplegia rate and I think one of the advantages of using
one short-body TX2 device followed by a long bare stent. Theoret-
ically, the observed enhanced false lumen ﬂow has minimized para-
plegia and combined with low mortality rates, it seems to do the
job while minimizing complications.
As far as the bare stent, from my standpoint, I think it comes
down to what your patient looks like anatomically. If they have
extensive malperfusion distally, then I would extend that bare stent
all the way down to the bifurcation; if it looked like there was a
very focal area, then I would minimize its coverage.
Dr Jon Matsumura (Madison, Wisc). What is the deﬁnition
of thoracic versus abdominal aorta? Is it at the diaphragm? Is it
at the celiac? Does abdominal aorta growth mean that these pa-
tients will require a type IV thoraco-abdominal repair?
If the abdominal aorta is deﬁned at the celiac, have you modi-
ﬁed your treatment in that when you need to go back and treat pa-
tients with abdominal aortic growth either with another renal stent
or maybe an open repair, how do you feel about having the bare
aortic stent there? Do you feel like there is a different approach
you should do at that initial operation that might make that second
repair simpler?
Dr Lombardi. We deﬁne the thoracic aorta from the celiac
and above, abdominal is below, based on our core lab data, and
that’s how they measured our false lumen patency.
Now, if you have a bare metal stent crossing through the peri-
visceral aorta, which 80 of our patients had, and then you notice
growth, having that stent there approximates the intima with
your target visceral artery. So if you’re looking to bring back the
target vessel that has a reentry tear back in continuity with the
true lumen, it’s much easier with the bare stent present. Working
through that stent is pretty facile, just like a fenestrated stent graft
at the end of it all. There are smaller little intimal tears that are
from the intercostals that may persist; however, when you tackle
the large entry tears, you usually minimize ﬂow to the degree
where you can stabilize growth.
Dr Juan Parodi (San Isidro, Argentina). I have a question. It
seems that we don’t have solutions yet for the abdominal aorta in
the long term, and we see these more and more as we follow our
patients’ dilatation of the abdominal aorta in type IIIb. It seems
that with your system you can achieve positive remodeling of the
true lumen. The problem is the false lumen. We are conducting
studies in which we are seeing that the diastolic pressure in the false
lumen is higher than in the true lumen and through numerical
models, and, mechanical models and some anecdotal measure-
ments, we are seeing that we need another treatment to completethis, either do percutaneous septotomy or perhaps using branches
and complete the occlusion of the entry sites of the distal aorta.
What do you think about it?
Dr Lombardi. I believe that’s largely true. Persistent ﬂow in
the false lumen and the abdominal aorta is the Achilles’ heel and
responsible for growth. I think from a basic standpoint covering
the reentry tears and minimizing ﬂow into that segment has sub-
stantial value in the setting of growth. It’s more or less anecdotal
at this point because we don’t have a host of patients to really to
compare with those who did not achieve those procedures. Sec-
ondary procedures, particularly if patients are treated in the acute
phase, are going to be common to this pathology and
management.
Dr Manju Kalra (Rochester, Minn). I just have two quick
questions for you. Do you have a theoretical explanation for
why you had continued growth in the group of patients that
were treated in the acute phase within the ﬁrst 2 weeks
compared to those treated later? And do you think, when you
have a larger group of patients, you’re going to be able to
make a recommendation as to preferred timing of treatment
based on this data?
Dr Lombardi. That’s the question, isn’t it? From the stand-
point of patients with malperfusion and rupture, you have no
choice. So you’re treating them when they present. Most of the pa-
tients who present in the acute phase have those two problems. So
from a standpoint of watchful waiting, and potentially waiting after
14 days to treat them, that might provide you some value in pa-
tients in whom you think you can wait on, but again that clinical
scenario rarely will come up.
As to why it happens, I don’t know. I think that in the acute
phase there is inﬂammation and a very suggestible intimal mem-
brane which maybe you set off a course or a series of events where
the aorta just is unable to stabilize. But I don’t have a very good
explanation for that at this time. We clearly need to follow those
patients closely, however.
Dr B. Timothy Baxter (Omaha, Neb). It looked like your
rupture rate was higher in the growth group versus the no-growth
group. Where are the ruptures occurring in these patients, and is
there something that you could be looking for to try to prevent
the rupture?
Dr Lombardi. We were unable to get an autopsy on the pa-
tients who ruptured, so we really don’t know exactly where that
occurred anatomically. They presented with back pain and most
of them expired before we could fully evaluate the location of their
ruptures. But we suspect they were all in the thoracic aorta.
However, you mentioned the increased rate of rupture in pa-
tients in the thoracic aorta with growth; although not signiﬁcant,
we had an equally converse situation in the abdominal aorta where
the patients who had no growth had a higher mortality and
rupture. So that was a little counterintuitive, not something I
would have predicted; however, that’s how it worked out. So,
based on the data thus far, we can’t predict rupture based on
morphology and growth.
